BioPharma Dive 20 janv. 2026 Kailera’s Ron Renaud on how a China-linked startup can compete in obesity
BioPharma Dive 20 janv. 2026 When every day counts: Building CRO partnerships on a foundation of trust, care and precision
BioPharma Dive 16 janv. 2026 Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading
BioPharma Dive 14 janv. 2026 JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view
BioPharma Dive 14 janv. 2026 Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill